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Cells continually experience stress and damage from 
exogenous and endogenous sources, and their responses 
range from complete recovery to senescence and cell 
death [1]. Proliferating cells cannot divide indefinitely 
due to the progressive shortness of their telomeres and 
after almost 60 population doublings (Hayflick limit) 
they stop to grow while remaining metabolically active 
[1]. Cells can also become senescent prematurely as a 
result of stressful events such as oncogene over-
expression and exposure to DNA damage (for example 
induced by UV radiation), or oxidative stress (ROS). 
This phenomenon, referred as premature senescence, 
occurs rapidly after the triggering event and is a 
mechanism implicated in cancer and aging. Recent 
studies have identified a novel type of cellular 
senescence response that occurs rapidly after 
inactivation of PTEN, the major regulator of the 
PI3K/AKT/mTOR pathway in both mouse and human 
primary cells [2]. Senescence driven by loss of PTEN is 























Cellular  senescence  is  a  stable  cell  cycle  arrest  that  is  the  causative  process  of  aging.  The  PI3K/AKT/mTOR
pathway  is  implicated  in  the  control  of  cellular  senescence  and  inhibitors  of  this  pathway  have  been
successfully  used  for  life  span  prolongation  experiments  in  mammals.  PTEN  is  the  major  regulator  of  the





human  epidermis. Mechanistically,  SH  treatment  affects  senescence  driven  by UV  by  interfering with  IL1‐α
signalling. Pre‐clinical and clinical testing of this extract by performing toxicity and irritability evaluation in vitro
also demonstrate the safety of SH extract for clinical use as anti‐aging skin treatment. 
www.aging‐us.com  3224  AGING (Albany NY) 
p53, a potent inducer of senescence [2]. Activation of 
the PI3K/AKT/mTOR pathway independent of PTEN 
loss is also implicated in replicative senescence, and 
inhibition of mTOR was shown to prevent ageing in 
different experimental in vivo models [3-6]. 
Interestingly, rapamycin and metformin two potent 
mTOR inhibitors, suppress geroconversion, prevent 
cancer and have minor side effects when administered 
long-term in anti-aging doses [7-22]. Activation of the 
PI3K/AKT pathway is also implicated in UV induced 
cellular senescence, a phenomenon known as photo 
ageing. Recent findings show that UV irradiation can 
activate AKT and mTOR, thus boosting senescence and 
photo aging [23-26]. Considering the need for cost 
effective active agents that prevent or arrest cellular 
senescence, efforts have been made to develop an assay 
for the identification of novel anti-senescence 
compounds [27, 28]. Natural compounds represent an 
extraordinary inventory of high diversity structural 
scaffolds that can offer promising candidates in the 
major healthcare challenge of delaying ageing [29]. 
Plant extracts provide a substantial source of potentially 
active compounds, however so far only few natural 
compounds have been reported to have anti-senescence 
effects [30-34]. Based on our previous research results 
[2], we developed an assay that uses Pten null cells as a 
tool to rapidly identify compounds that decrease 
senescence in primary cells. Positive hits are later on 
tested in human primary cells to validate their anti-
senescence efficacy in replicative and UV-mediated 
senescence assays.  
 
Here, we report the results of the screening of more than 
3000 substances of both natural (plants and marine 
extracts) and chemical source. Our data demonstrate 
that an extract derived from the Salvia haenkei (SH) 
plant is a strong inhibitor of senescence driven by loss 
of Pten, senescence associated to replicative stress and 
photo aging, both in mouse and human primary cells. 
Furthermore, we have evaluated in vitro the toxicity and 
irritability of SH on a model of reconstructed human 
epidermis (EpiSkin) demonstrating SH safety for the 




A screening platform for the identification of anti-
senescence compounds 
 
Loss of Pten drives a cellular senescence response in 
primary cells termed Pten loss induced cellular 
senescence (PICS) [2]. We have recently developed an 
effective method for identification of pro-senescence 
compounds to be used for cancer therapy [35]. By 
modifying this screening assay, we developed a 
screening platform, for identification of compounds 
with anti-senescence activity for the treatment of aging 
and aging-related disorders (Fig. 1). As previously 
reported [2], upon inactivation of Pten, 30-40% of the 
cells undergo to senescence within 4 days. This 
provides a screening window to identify hits that affect 
senescence in a short time frame, something that would 
be complicated by using a different senescence assay 
(e.g. replicative senescence). Compounds that decreased 
the percentage of senescent cells in the screening 
platform were designated as anti-senescence 
compounds based on two parameters: 1) cell 
proliferation and 2) inhibition of SA-β-galactosidase 
staining (SA-β-gal), a prototypical senescence marker 
[36]. For the identification of new anti-senescence hits, 
the library was created from 3065 substances 
comprising 1) chemical molecules (2500) 2) blue 
marine extracts (252) 3) plant extracts (313) as reported 
in Fig. 1a. Pten lx/lx MEFs were infected with a retro-
viral Cre vector to delete Pten and selected for two days 
with puromycin to obtain Pten-/- MEFs (t0). 
Experimentally, the screening was carried out in three 
steps using Pten-/- MEFs (Fig. 1b and Supplementary 
Fig. S1a). In the first step, compounds were studied in 
triplicates using a single concentration (10 µg/ml). Cells 
were treated for 5 days from t0. Candidate compounds 
that increased the cell growth rate of more than 30% 
compared to control (n=80/3065), were considered as 
potentially anti-senescent hits and were retested in 
triplicate. Validated hits (n=54/80) were tested for SA-
β-galactivity subsequently. Compounds that decreased 
the SA-β-gal staining more than 30% (compared to 
DMSO treated Pten-/- cells), passed this filter. Among 
these hits there were 11 extracts from plants, sponges 
and marine bacteria and 5 chemical compounds, 
demonstrating that nature is a valuable source of 
biologically active phytochemicals that can slow down 
senescence (Fig. 1c, d).  Interestingly, 1/16 hit was plant 
extract of Angelica whereas, 8/16 hits were plant 
extracts of Salvias, the largest genus of plants in the 
family Lamiaceae, with the number of species estimated 
to range from 700 to nearly 1,000 members. 2/16 hits 
were from a sponge extract and a marine bacterium 
associated to a sponge respectively, whereas 5/16 hits 
were small molecule inhibitors (Supplementary Table 
S1a). The most potent of these hits was an extract of 
Salvia haenkei (SH) a member of the family of Salvias, 
native of Bolivia. SH decreased senescence of 50% 
when compared to untreated control, by-passing the 
growth arrest promoted by Pten loss (Fig. 2a-d). 
Interestingly, Pten null cells treated with SH had a 
growth rate similar to Pten wt cells. Pten wt cells also, 
did not significantly increase proliferation after SH 
treatment when compared to vehicle treated control 
(Supplementary Fig. S1b). HPLC analysis revealed that 
SH extract contained high levels of apigenin and 
luteolin glycosides, two flavonoids with anti-cancer 
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properties [37] (Supplementary Fig. S1c and Supple-
mentary Table S1b). 
 
Identification of compounds that prevent replicative 
and radiation-driven senescence 
 
To assess whether identified hits decrease replicative 
senescence in vitro, we used human dermal fibroblasts. 
To this extent we carried on a series of experiments 
using the 3T3 protocol in the WI38-CCL75 cells for a 
period of over 3 months. Cells were plated and 
subsequently passed and re-plated in the same number 
every 3 days, in the presence or absence of selected hits. 
Only four out of 16 hits (2 plants and 2 marine extracts) 
were able to decrease replicative senescence and were 
further developed in our screening cascade. Among 
these extracts, SH showed again the most relevant 
activity (Supplementary Fig.  S2a). As represented in 
Fig. 3a, while untreated cells stopped growing at 
passage 30, cells treated with SH continued to 
proliferate. Moreover, senescence in treated cells was 
significantly decreased when compared to control as 
assessed by the SA-β-Gal staining (Fig. 3b). The 
reduction in the percentage of SA-β-Gal staining in 
these cells was comparable to the one observed in Pten 
null MEFs showing a correspondence between these 
two models. Importantly, treatment of cells with SH for 
a period of three months was not associated to increased 
cell death, as demonstrated by the cell viability assay 
(Fig. 3c). Taken together, these data demonstrate that 
 
 
Figure 1. Schematic  representation of  the platform  for  the  in vitro  identification of anti‐senescent  compounds.  (a) 
Number  of  chemical  and  natural  extracts  from  the  plants  and  blue  marine  ecosystem  used  for  the  screening.    (b)  Schematic 
representation of  the screening  steps.  (c‐d) Cytostatic and cytotoxic compounds were excluded  from  the screening and only anti‐
senescence  hits  progressed.  Compounds  that  induced  a  statistically  significant  increase  (of  40%  or  more)  in  cell  growth  were 
considered potential anti‐senescent candidates.  Instead, compounds that  induced a statistically significant decrease  in cell number 
were considered pro‐senescent (40% to 60% decrease), and cytotoxic (more than 60% decrease). 
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SH extract is a potent suppressor of PICS and 
replicative senescence in human primary dermal 
fibroblasts. Next, we assessed the anti-senescence 
activity of SH in an assay of senescence driven by UV 
irradiation. We set up experimental conditions to induce 
premature senescence using UV irradiation in WI38-
CCL75 human fibroblasts and assess senescence by 
performing SA-β−Gal staining at 24 and 48 hours after 
irradiation. SH treatment was able to prevent growth 
arrest and senescence in irradiated fibroblasts already at 
24h after treatment (Fig. 4a, b). At a later time point 
(48h) the effect of SH resulted even more efficient, 
mildly stimulating the proliferation of the control cells 
as well. Taken together, these data demonstrate that SH 
is a powerful anti-senescence agent in PICS, replicative 
senescence and cells treated with UV irradiation.  
 
Salvia haenkei extract reduce oxidative stress 
mediated by H2O2 
 
Next, we assessed the efficacy of SH in cells 
undergoing to oxidative stress. While ROS are produced 
as a product of normal cellular functioning, excessive 
amounts can cause deleterious effects. Oxidative stress 
also promotes cellular senescence and premature aging 
in the skin [38]. MEFs and human dermal fibroblasts 
were treated with H2O2 - a potent inducer of ROS. The 
antioxidant activity of SH (0.1-10µg/ml) was assayed in 
Figure 2. Effect of S. haenkei  treatment on growth arrest and senescence  in Pten‐/‐ MEFs.  (a) Proliferation of Pten‐/‐ 
MEFs in culture after 5 days of treatment with S. haenkei extract. Pten ‐/‐ MEFs were plated in concentration of 2x104 cells/ml and 
treated  for 5 days with 10µM MDM2i  (Nutlin‐3) or 10µg/ml SH extract. After  this period,  the proliferation was determined using 
Crystal violet staining. (c) Results are expressed as mean values (+SEM) of absorbance at 590nm for duplicates treated with SH and 
triplicate  for  control  and Nutlin‐3  treated  groups,  from  one  representative  experiment  out  of  3  independent  experiments.  (b‐d) 
Senescence of Pten‐/‐ MEFs    in  culture after 5 days of  treatment with S. haenkei extract. The graph  represents percentage of  β‐
galactosidase positive cells  revealed  in culture upon 5 day  treatment with 10µM MDM2i  (Nutlin‐3) or 10µg/ml S. haenkei extract. 
Quantifications were done on 4  images (roughly 500 cells) per experiment by determining the ratio of perinuclear blue–positive to 
perinuclear blue–negative cells. Results are expressed as mean values (+SEM) of cell count in three independent experiments.  
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MEFs and human fibroblasts immediately after the 
exposure to H2O2. Interestingly, SH treatment in MEFs 
reduced the intracellular levels of ROS both in untreated 
cells and in cells treated with H2O2. The effect of SH in 
these cells was similar to that of N-acetylcysteine 
(NAC), a known antioxidant compound clinically used 
to prevent the accumulation of ROS in different 
inflammatory conditions [39] (Fig. 5a, b). A similar 
effect was also observed in human fibroblasts treated 
with and without H2O2 (Fig. 5c, d). Taken together, 
these data demonstrate that SH treatment decreases the 
intracellular levels of ROS thereby explaining its 
efficacy in preventing different types of senescence. 
 
Salvia haenkei treatment decreases senescence in a 
human 3-D skin model (EpiSkin), by interfering with 
IL1α secretion 
 
To assess the efficacy and safety of SH in a human skin 
model we took advantage of the EpiSkin model that has 
been recognized as a valid alternative to animal test 









each passage. Quantifications were done on 4  images  (roughly 500  cells) per experiment by determining  the  ratio of perinuclear 
blue–positive  to perinuclear blue–negative  cells. Results  are  expressed  as mean  values  (+SEM) of  cell  count  in  four  independent 
experiments.  (c)  Cell  death  in  culture  of  human WI38  fibroblasts  upon  treatment with  S.  haenkei  extract.  The  graph  represents 
percentage of Trypan blue positive (dead) cells revealed in culture at each passage. Quantifications were done on one experimental 
image (roughly 100 cells) in one representative experiment. 
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human epidermis from normal human keratinocytes 
cultured on a collagen matrix at the air-liquid interface. 
This model is histologically similar to the in vivo human 
epidermis [41]. To assess the anti-senescence potential 
and toxicity of SH extract following topical treatment 
we delivered SH in an oil-in-water conventional skin 
care vehicle. Human epidermis was treated with UV in 
the presence or absence of SH (10µg/ml) and SA-β-Gal 
staining was assessed 42h after treatment. 
Quantification of SA-β-Gal staining showed that SH 
decreased the number of senescent cells in the human 
epidermis validating our previous results (Fig. 6a). 
Next, we checked the levels of IL-α secreted by the 
human epidermis in the culture media of samples 
treated with UV +/- SH. Recent findings demonstrate 
that IL1α is an essential regulator of paracrine 
senescence since it can control the senescence-
associated secretory phenotype (SASP) [42]. Indeed, 
senescent cells can release IL1α in the 
microenvironment to promote senescence in normal 
cells. This phenomenon has been proposed as the cause 
of the progressive increase of senescent cells in normal 
tissues during aging. Surprisingly, SH treatment 
suppressed also the levels of IL1α released by the 
human epidermis after treatment with UV and this 
correlated with a decreased SA-β-Gal staining (Fig. 6a 
and b). Taken together, these data demonstrate that SH 
treatment decreases paracrine senescence by interfering 
with IL1α released by senescent cells.  A cell viability 
assay excluded any cytotoxic activity of SH in cells 
treated with this compound also in this model (data not 
shown). Note that as control for this experiment, we 
used SDS treatment. SDS is an irritant known to 
promote the secretion of IL1α. Therefore, these data 
also demonstrate that SH treatment does not irritate 




Cellular senescence is a stable cell growth arrest that 
occurs in almost all the cells of human tissues during 
aging [1]. By definition, senescent cells remain arrested 
even in the presence of growth factors, but are 
metabolically active and stain positive for SA-β-gal at 
pH6, a marker of enhanced lysosomal activity [36]. 
Senescent cells can also release in the tissue 
microenvironment several factors known collectively as 






each  group  in  one  representative  experiment  out  of  three  independent  experiments.  (b)  Senescence  of  irradiated  human WI38 
fibroblasts treated with S. haenkei extract. The graph represents percentage of β‐galactosidase positive cells revealed  in culture at 
time points 24h and 48h. Quantifications were done on 4  images  (roughly 500  cells) per experiment by determining  the  ratio of 
perinuclear  blue–positive  to  perinuclear  blue–negative  cells. Results  are  expressed  as mean  values  (+SEM)  of  cell  count  in  three 
independent experiments.  
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[1]. These factors can also propagate senescence to 
neighboring cells, a process known as paracrine 
senescence. Through the SASP, senescent cells can 
induce deleterious effects on normal tissues. Mice, 
whose senescent cells were killed off, were healthier 
than transgenic mice in which these cells accumulated 
as effect of aging. Kidneys and heart  function in these 
mice were enhanced; moreover, they were less prone to 
develop cancers than control animals [43]. Thus, 
therapies that prevent the accumulation of senescence 
cells in normal tissues or that selectively kill senescent 
cells (senolytic therapies) could be used for the 
treatment of aging and aging associated disorders such 
as cancer, neurodegenerative and cardiovascular 
diseases. Eliminating senescent cells could also extend 
the lifespans of health subjects as recently demonstrated 
in the mice [43]. We have previously identified a novel 
type of senescence response, which occurs rapidly after 
inactivation of PTEN, an essential regulator of the 
PI3K/AKT/mTOR pathway in both mouse and human 
cells [2, 44]. Several evidence demonstrates that the 
PI3K/AKT pathway is implicated in different types of 
cellular senescence response, including replicative 
senescence, oncogene-induced senescence (OIS) and 
photoaging [2, 44, 45]. Inhibition of mTOR, a crucial 
downstream component of this pathway, attenuates 
senescence and prolongs the life span of mice [7, 46]. 
This effect is probably due to the attenuation of the 
SASP rather than to telomeres preservation as 
demonstrated by recent findings. Indeed, mTOR 
inhibition blocks some of the negative effects of the 
SASP and these compounds may therefore be clinically 
developed for the prevention of aging or aging related 
disorders [47, 48]. Currently, there is a high demand for 
compounds of natural origin that can block senescence 
to be used as gerosuppressants. Using Pten null cells as 
 
Figure  5.  Effect  of  S.  haenkei  treatment  on  ROS  production  on MEFs  and  human  fibroblasts.  ROS  generation were 
measured after 3 hours of incubation in untreated cells and after H2O2 exposure. Treatment with NAC was used as positive control. 
Data are expressed as mean ± SEM percentage of basal  (100%) DCF  fluorescence  intensity  (FI) of  three  independent experiments. 
**p<0.05 treated vs untreated. (a) ROS production in unstressed MEFs; (b) ROS production in MEFs after exposure to H2O2; (c) ROS 
production in unstressed human fibroblasts; (d) ROS production in human fibroblasts after exposure to H2O2. 
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a model, we have developed a screening assay to 
identify compounds that block senescence. Inactivation 
of the tumor suppressor PTEN promotes a strong 
cellular senescence response that limits the replicative 
lifespan of primary cells, which exhibit a characteristic 
enlarged and flattened morphology and increased SA-β-
Gal activity. Without ideal means to develop a 
completely automated screen, we developed a 
pragmatic semi-automated approach using a high-
throughput screening followed by visual assessment of 
cells of interest, achieved by crystal violet and SA-β-
Gal , two standard and accepted assays  used to identify 
senescent cells [49]. The use of these 2 assays in Pten 
null cells greatly reduces the time and resources 
required to make the initial identification of potential 
hits, and although not completely automated, these 
methods are nonetheless rapid.  Herein, we confirm that 
in contrast to chemical compounds, which showed very 
little percentage of active anti-senescence compounds, 
natural compounds affected cellular senescence with 
much higher rate. The identification of natural 
compounds as regulators of anti-senescence and anti-
oxidant is critical in the discovery of novel therapeutics. 
Using this screening platform, we have identified Salvia 
haenkei as anti-senescent plant extract and tested it for 
replicative senescence and photo ageing prevention.  
Importantly, our experiments in a model of skin human 
epidermis (EpiSkin) demonstrate that SH extract can 
decrease the levels of senescence cells by affecting the 
secretion of IL1α. IL1α is considered the master 
regulator of the SASP and a recent paper demonstrates 
that compounds that interfere with IL1 signaling blocks 
replicative senescence, OIS and PICS [49,50].  Taken 
together, these data suggest that SH extract may be 
safely used in a skin-care preparation to prevent skin 
aging also in consideration of the found SH anti-
microbial activity (Supplementary Fig. S2b). 
Replicative and UV-mediated senescence in skin are 
responsible of wrinkling, pigment changes, cracking 
and loss of elasticity among others. Acute dermal 
overexposure to UV radiation also causes an 
inflammatory response, erythema and leukocyte 
infiltration [51]. Oxidative stress initiated by ROS 
generation is also an important mediator of cellular 
aging, including skin aging. As demonstrated here, SH 
treatment also decreased ROS levels in cells treated 
with H2O2 at early and late time points. Finally, 
experiments in the EpiSkin model also demonstrate that 
 
Figure 6. Toxicity and  irritability evaluation of S. haenkei extract  in reconstituted human epidermis. Skin  issues were 
cultured in 12 well plates containing 37°C pre‐warmed maintenance media (2 ml/well) and incubated overnight at 37°C, 5% CO2 and 
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a skin care preparation containing SH extract is safe and 
not irritant for the human skin. In sum, our findings 
describe novel screening assays for the identification of 
gerosuppressant agents. Previous screenings have 
reported the identification of anti-aging compounds 
using different biological systems (e.g. yeast) and 
assays (e.g. in vitro assays, computer screening). Since 
the pathways that control aging in mammals have 
homologs in yeast, flies, and worms, several of these 
screenings have been performed in invertebrates instead 
that in mammalian cells [52-54]. These screenings have 
contributed to the identification of several 
gerosuppressants active compounds such as rapamycin, 
metformin and resveratrol whose efficacy have been 
later on validated in mammalian cells. Our screening 
based on the use of PTEN deficient mouse embryonic 
fibroblasts in a first step and in the consecutive 
validation of positive HITs in human cells offers a 
promising alternative to these models for the rapid 
identification of effective gerosuppressants. 
 
MATERIALS AND METHODS 
 
Plant material and preparation of plant extract 
 
The extract of Salvia haenkei was kindly provided by 
Dr. Bisio from Dept. of Chemistry and Pharmaceutical 
Technologies, University of Genoa, Italy. The plant 
material was harvested and leaves were put in a 
ventilated stove at 45°C for 24 hours, and then ground 
as fine powder using a mixer IKA universal M20. A 
quantity of 20.0g of powdered dried plant was weighed 
in a 100ml conical flask to which 70ml of hexane 
(purity 99%) was added for the pre-extraction. The flask 
was placed in a bath sonicator (Branson 8210) and 
sonicated at a temperature of 40°C for 30 minutes. The 
mixture was filtered with filter paper, followed by 
washing with 20ml of hexane and then with 50ml of 
hexane. The filtrate was poured into a flask and the 
solvent was concentrated under vacuum (about 
11mmHg) up to 5-10 ml by rotavapor, using a water 
bath at 40°C. This residue as poured into a glass 
container followed by evaporation of the solvent. The 
filtrate was left open overnight in a well-ventilated hood 
until complete evaporation of the last traces of solvent. 
The solids collected on the filter, were divided and air-
dried overnight in the hood. The dried material is 
extracted in the same way with methanol-water (90:10). 
The dried material from the filters was dissolved in 
70ml of 90% methanol. The mixture was sonicated at 
40°C for 30 minutes, after being filtered, then washed 
with 20 ml of 90% methanol. The filtrate was poured 
into a flask and the solvent completely evaporated under 
vacuum. The dry extract was dissolved in 90% 
methanol in the least possible amount of absolute 
methanol, using sonication and poured into a glass 
container to evaporate overnight in the hood. The 
extract was reconstituted with pure DMSO at a 
concentration of 10mg/ml and kept at -20°C until 
dilution for the treatment of cell cultures. The SH 
extract was analysed by HPLC-DAD and HPLC-MS 
obtaining a phytochemical fingerprint. The identified 
constituents are summarized in supplementary data 





Ptenlx/lx MEFs were prepared as previously described 
[36]. Briefly, pregnant female mice at day 13 
postcoitum (assuming as day one the first day the plug 
was observed) were sacrificed by cervical dislocation. 
The uterine horns were dissected out, briefly rinsed in 
70% (v/v) ethanol and placed into a petri dish 
containing PBS (Gibco 14190-169, without bivalent 
cations). Each embryo was separated from its placenta 
and surrounding membranes, the brain and dark red 
organs were cut out. Embryos were washed with fresh 
PBS, removing as much blood as possible. Using a 
minimal amount of PBS and razor blades, the embryos 
were finely minced into a suspension of cells to which 
several ml of trypsin-EDTA (about 1-2ml per embryo, 
Gibco 25300-096) was added. Following incubation 
with gentle shaking at 37°C for 15min the resulting cell 
suspension was pelleted and resuspended in fresh 
DMEM (ReadyMix, PAA) containing 10% FCS, 2mM 
L-glutamine, 2mM penicillin, 50µg/ml streptomycin. 
Cells were plated out at 1 embryo equivalent per 10cm 
dish ("passage No. 0"). The adherent fibroblasts reached 
confluence at day 4 when they were collected and 
stored at -80°C prior to use in the APICS assay (for 
details of this assay see also Fig. 1 and Supplementary 
Fig. S1a)  
 
Cell cultures and infections 
 
Ptenlx/lx MEFs were isolated as described previously 
[36]. To produce Pten-/- MEFs, Ptenlx/lx MEFs were 
subsequently infected with a viral vector retro- Cre - 
recombinase (Adgene Plasmid pMSCV PIG Cre (Cre 
IRES Puro vector)). This retro-Cre was produced by 
transfection of Phoenix cells (Eco and Ampho from Life 
Technologies) at 70-80% confluence using 
Lipofectamine 2000 (Invitrogen). At 70% confluence, 
Ptenlx/lx MEFs were infected with supernatant from 
Phoenix cells, collected after 48h of transfection with 
retro-Cre vector. To increase the efficiency of infection 
5μg/ml Polybrene (Santa Cruz) was used. 12h after the 
first infection, Ptenlx/lx MEFs infection was repeated. 
24h later, infected Ptenlx/lx MEFs were selected with 
3μg/ml puromycin. 48h later, Pten-/- were plated and 
treated with compounds within APICS molecular 
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screening assay. As control (Ptenwt) cells in APICS 
assay we used Ptenlx/lxMEFs infected with a viral vector 
retro- PIG (Adgene plasmid pMSCVPIG (Pure 
IRESGFPvector)), resistant to puromycin, by following 
the same protocol as described for Pten-/- MEFs. Human 
WI38-CCL75 fibroblast cell line (ATCC) was used for 
3T3 assay and UV irradiation experiments. All cell 
cultures were maintained in fresh DMEM (ReadyMix, 
PAA) containing 10% FCS, 2mM L-glutamine, 2mM 
penicillin, 50µg/ml streptomycin.  
 
Cell proliferation and viability 
 
Cell proliferation was measured using staining with 
Crystal violet colour (Sigma Aldrich). Cells were per-
fixed with 4% formaldehyde for 15min., washed with 
PBS and stained with 0.1% Crystal violet for 20 
minutes. After 3 wash cycles with PBS, cells were lysed 
in 10% acetic acid and color intensity read at 590nm on 
SUNRISE ELISA reader (Tecan, Switzerland). Growth 
curve analysis was carried out as previously described 
in literature [55]. Cell viability was assessed using 




Senescence staining was performed using the 
commercial Senescence Detection Kit (Calbiochem, 
#JA7633), designed to histochemically detect β-gal 
activity in cultured cells at pH 6.0. β-gal at pH 6.0 is 
present only in senescent cells and is not found in 
presenescent, quiescent, or immortal cells. Standard 
protocols were followed [56], and quantifications were 
done on 4 images (roughly 500 cells) per experiment by 
determining the ratio of perinuclear blue–positive to 
perinuclear blue–negative cells. Fluorescent nuclear 
staining was performed using 4',6-diamidino-2-




Human primary fibroblasts WI38-CCL75 were plated in 
10cm2 dishes (3x105cells/dish), and subsequently 
passed and re-plated in the same number every 3 days 
for total of 24 passages up to the point when treatment 
was initiated. At passage 25, cells were plated at the 
same number and treated with the SH extract in single 
concentration (10µg/ml). Every 3 days cell number was 
determined by Trypan blue counting, cells re-plated and 
re-treated. At passages 28, 29 and 30 senescence was 
evaluated by measuring β-gal expression.  
 
UV irradiation assay 
 
We tested SH extract for the ability to prevent 
senescence in a model of UVB irradiated human 
fibroblast primary cells. To this purpose, WI38-CCL75 
human fibroblasts were irradiated with the optimized 
non cytotoxic dose (30J/m2) of UVB irradiation that 
causes senescence. 3h after irradiation, positive hits 
were added in single concentration (10µg/ml). Cell 
proliferation was determined at different time points 
using crystal violet assay. Senescence was measured by 




ROS were quantified using 2′,7′-dichlorofluorescin-
diacetate (H2-DCF-DA, Sigma-Aldrich), as previously 
described [57]. Upon cleavage of the acetate groups by 
intracellular esterase and oxidation, the H2-DCF-DA is 
converted to the fluorescent 2',7'-dichlorofluorescein 
(DCF). Briefly, the cells (5×103) were seeded into 96-
well plates and allowed to adhere overnight. ROS level 
was measured after the exposure to SH extract for 3 
hours in the absence or presence of H2O2, and 
subsequent addition of 50 μM H2-DCF-DA, further 
incubation for 30 min at 37°C and washing with 
phosphate-buffered saline (PBS). DCF fluorescence 
intensity was measured at excitation 485 nm—emission 
535 nm, using a Multilabel Plate Reader VICTOR X3 
(PerkinElmer). Fold increase in ROS production was 
calculated using the equation: (Ftreatment—





The EpiSkinLM model (LM: large model; 
manufactured by EPISKIN S.N.C., Lyon, France) is a 
reconstructed organotypic culture of human adult 
keratinocytes that reproduce a multilayered and 
differentiated human epidermis. Briefly, human adult 
keratinocytes were seeded on a dermal substitute 
consisting of a collagen I matrix coated with a layer of 
collagen IV fixed to the bottom of a plastic chamber. 
Epithelial differentiation was obtained by an air-
exposed step leading to a 3-dimensional epidermis 
construct (1.07cm2 surface), with basal, spinous, 
granular layers (with specific markers) and a stratum 
corneum. EpiSkinLM units were delivered to the 
laboratory within 24 hours after preparation. Upon 
arrival, tissues were transferred to 12 well plates 
containing 37°C pre-warmed maintenance media (2 
ml/well) and incubated overnight at 37°C, 5% CO2 and 
95% humidity. Skin units were treated with 30J/m2 of 
UVB irradiation. SH extract (10µg/ml) was formulated 
in a standard oil emulsion and applied topically to the 
surface of the epidermis. 4h after UV irradiation, the 
epidermis was washed with PBS and left for incubation 
at 37°C, 5% CO2. 42h later, supernatants were collected 
and stored at -80°C. To assess toxicity of the extract, 
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cell viability test was performed using MTT assay (In 
Vitro Toxicology Assay Kit, Sigma Aldrich) (data not 
shown) and to assess the release of IL-1α, we analysed 
collected supernatants by ELISA (Abcam) for presence 
of IL-1α. For the quantification of senescence in the 
EpiSkinLM modelfrozen sections of skin units (6μm 
thick) were stained for SA-β-Gal as described above, 




Supernatants of EpiSkin epidermis, derived in different 
conditions (negative control-PBS, positive control-SDS 
and treatment with SH extract 10µg/ml) were collected 
and stored at -800C. IL-1α (limit of sensitivity < 10 
pg/ml) levels were determined by ELISA kit (Abcam) 
according to the manufacturer’s specifications. Results 
are expressed as pg/ml and reported as means from 




All values obtained are means of at least three 
independent experiments performed in duplicate or 
triplicate. Results are presented as mean value ± SEM. 
Control and treated groups were compared using the 
analysis of variance (ANOVA) test. In all analyses, a p-
value of <0.05 was considered statistically significant. 
Data were processed using Assistat (version 7.6b) and 
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